Biomerieux SA (BIM.PA) stock: key figures, P/E, revenue and dividend
Health Care · France · ISIN FR0013280286
Biomerieux SA financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 3.98 bn EUR | 4.07 bn EUR |
| Gross profit | 2.22 bn EUR | 2.14 bn EUR |
| Operating income | 637.90 m EUR | 694.80 m EUR |
| EBIT | 588.00 m EUR | 561.00 m EUR |
| Net income | 432.00 m EUR | 397.00 m EUR |
| Diluted EPS – continuing operations | 3.63 EUR | 3.34 EUR |
Full history since 2001, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Biomerieux SA
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making. It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of an antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.
More stocks
- RoboTechnik Intelligent Technology Co Ltd (300757.SZ)
- Phison Electronics (8299.TWO)
- ANTERO RESOURCES Corp (AR)
- Maplebear Inc. (CART)
- American Healthcare REIT, Inc. (AHR)
- Kawasaki Heavy Industries Ltd (7012.T)
- Sprott Physical Silver (PSLV.TO)
- Pearson PLC (PSON.L)
- ARROW ELECTRONICS, INC. (ARW)
- Mirae Asset Daewoo Securities Co Ltd (006800.KS)
- CP ALL Public Company Limited (CPALL.BK)
- Bio-Techne (TECH)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.